CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 72 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,954,082 | +624.7% | 401,953 | +339.1% | 0.03% | +700.0% |
| Q2 2023 | $1,649,461 | +219.0% | 91,535 | +184.3% | 0.00% | +300.0% |
| Q1 2023 | $517,132 | +14.8% | 32,200 | +30.8% | 0.00% | 0.0% |
| Q4 2022 | $450,400 | -1.4% | 24,612 | +5.8% | 0.00% | -50.0% |
| Q3 2022 | $457,000 | -47.6% | 23,256 | -50.2% | 0.00% | -33.3% |
| Q2 2022 | $872,000 | -67.1% | 46,745 | -61.3% | 0.00% | -62.5% |
| Q1 2022 | $2,651,000 | -32.0% | 120,777 | -12.0% | 0.01% | 0.0% |
| Q4 2021 | $3,900,000 | +26.7% | 137,292 | -6.2% | 0.01% | +14.3% |
| Q3 2021 | $3,079,000 | +40.5% | 146,292 | +25.8% | 0.01% | +40.0% |
| Q2 2021 | $2,192,000 | +147.7% | 116,310 | +100.7% | 0.01% | +150.0% |
| Q1 2021 | $885,000 | +16.3% | 57,944 | +7.5% | 0.00% | 0.0% |
| Q4 2020 | $761,000 | +79.5% | 53,911 | +99.1% | 0.00% | 0.0% |
| Q3 2020 | $424,000 | -55.0% | 27,077 | -49.7% | 0.00% | -60.0% |
| Q2 2020 | $943,000 | – | 53,812 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |